Pro: Pulse Oximetry Is Useful in Predicting Acute Mountain Sickness

Basnyat B , Gertsch JH , Johnsosn EW , Castro-Marin F , Inoue Y , and Yeh C . (2003). Efficacy of low-dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: A prospective, double-blind, randomized, placebo-controlled trial. High Alt Med Biol, 4:45–52.

Basnyat B , P. S. Holck PS , and Pun M . (2011). Spironolactone does not prevent acute mountain sickness: A prospective, double-blind, randomized, placebo-controlled trial by SPACE Trial Group (spironolactone and acetazolamide trial in the prevention of acute mountain sickness group). Wilderness Environ Med, 22:15–22.

Basnyat B , and Murdoch DR . (2003). High-altitude illness. Lancet, 361:1967–1974.

Burtscher M , Szubski C , and Faulhaber M . (2008). Prediction of the susceptibility to AMS in simulated altitude. Sleep Breath, 12:103–108.

Chen H.C , Lin WL , and Wu JY . (2012). Change in oxygen saturation does not predict acute mountain sickness on Jade Mountain. Wilderness Environ Med, 23:122–127.

Dehnert C , Luks AM , and Schendler G . (2010). No evidence for interstitial lung oedema by extensive pulmonary function testing at 4,559 m. Eur Respir J, 35:812–820.

Faulhaber M , Wille M , Gatterer H , Heinrich D , and Burtscher M . (2014). Resting arterial oxygen saturation and breathing frequency as predictors for acute mountain sickness development: A prospective cohort study. Sleep Breath, 18:669–674.

Ge RL , Matsuzawa Y , Takeoka M , Kubo K , Sekiguchi M , and Kobayashi T . (1997). Low pulmonary diffusing capacity in subjects with acute mountain sickness. Chest, 111:58–64.

Gertsch JH , Basnyat B , Johnson EW , Onopa J , and Holck PS . (2004). Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: The prevention of high altitude illness trial (PHAIT). BMJ, 328:797.

Karinen HM , Peltonen JE , Kahonen M , and Tikkanen HO . (2010). Prediction of acute mountain sickness by monitoring arterial oxygen saturation during ascent. High Alt Med Biol, 11:325–332.

Luks AM , and Swenson ER . (2011). Pulse oximetry at high altitude. High Alt Med Biol, 12:109–119.

Richalet JP , Larmignat P , Poitrine E , Letournel M , and Canoui-Poitrine F . (2012). Physiological risk factors for severe high-altitude illness: A prospective cohort study. Am J Respir Crit Care Med, 185:192–198.

Roach RC , Oelz O , Hackett PH ., Ed. (1993). Lake Louise AMS Scoring Consensus Committee. The Lake Louise acute mountain sickness scoring system. Hypoxia Mol Med Burlington, Vt.: Charles S. Houston, 272–274.

Roach RC , Greene ER , Schoene RB , and Hackett PH . (1998). Arterial oxygen saturation for prediction of acute mountain sickness. Aviat Space Environ Med, 69:1182–1185.

Tannheimer M , Albertini N , Ulner HV , Thomas A , Engelhardt M , and Schmidt R . (2009). Testing individual risk of acute mountain sickness at greater altitudes. Mil Med, 174:363–369.

Tannheimer M , Thomas A , and Gerngross H . (2002). Oxygen saturation course and altitude symptomatology during an expedition to broad peak (8047 m). Int J Sports Med, 23:329–335.

Wagner DR , Knott JR , and Fry JP . (2012). Oximetry fails to predict acute mountain sickness or summit success during a rapid ascent to 5640 meters. Wilderness Environ Med, 23:114–121.

Windsor JS . (2012). Pulse oximetry and predicting acute mountain sickness: Are we asking the right questions?. Wilderness Environ Med, 23:112–113.

Zafren K . (2012). Prediction of acute mountain sickness by pulse oximetry: What are the right questions?. Wilderness Environ Med, 23:377–378.